CD68 and melanoma: As an example, in two different studies with melanoma patients treated with Nivolumab or Pembrolizumab, responder biopsies displayed an increase in CD8+ T cells in both studies, but in one case there was a reduction in the macrophage transcriptomic signature (92), while in the other there was an increase in peritumoral CD68+ macrophages after treatment (48).